These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 2110387)
21. Treatment of cancer-related hypercalcemia: the role of gallium nitrate. Leyland-Jones B Semin Oncol; 2003 Apr; 30(2 Suppl 5):13-9. PubMed ID: 12776255 [TBL] [Abstract][Full Text] [Related]
22. [Treatment of hypercalcemia of tumoral origin with two diphosphonates]. Jung A; van Ouwenaller C; Chantraine A; Courvoisier B Schweiz Med Wochenschr; 1980 Nov; 110(48):1822-4. PubMed ID: 6792698 [TBL] [Abstract][Full Text] [Related]
23. Pathophysiology and management of severe hypercalcemia. Nussbaum SR Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291 [TBL] [Abstract][Full Text] [Related]
24. Etidronate disodium: a new therapy for hypercalcemia of malignancy. Proceedings of a symposium. Am J Med; 1987 Feb; 82(2A):1-78. PubMed ID: 3103434 [No Abstract] [Full Text] [Related]
25. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy. Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992 [TBL] [Abstract][Full Text] [Related]
26. Treating cancer-related hypercalcemia with gallium nitrate. Leyland-Jones B J Support Oncol; 2004; 2(6):509-16. PubMed ID: 15605917 [TBL] [Abstract][Full Text] [Related]
27. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Guay DR Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795 [TBL] [Abstract][Full Text] [Related]
31. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208 [TBL] [Abstract][Full Text] [Related]
32. [Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. Lortholary A Rev Med Interne; 2001 Jul; 22(7):648-52. PubMed ID: 11508158 [TBL] [Abstract][Full Text] [Related]
33. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Meythaler JM; Korkor AB; Nanda T; Kumar NA; Fallon M Arch Intern Med; 1986 Aug; 146(8):1567-71. PubMed ID: 3089187 [TBL] [Abstract][Full Text] [Related]
34. [Medical treatment of malignant hypercalcemia]. Eto S; Nakano Y; Okada Y Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844 [TBL] [Abstract][Full Text] [Related]
35. Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. Meythaler JM; Tuel SM; Cross LL Arch Phys Med Rehabil; 1993 Mar; 74(3):316-9. PubMed ID: 8439262 [TBL] [Abstract][Full Text] [Related]
36. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601 [TBL] [Abstract][Full Text] [Related]
37. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. McMahan J; Linneman T Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757 [TBL] [Abstract][Full Text] [Related]
38. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198 [TBL] [Abstract][Full Text] [Related]